Skip to main content

USPTO Allows Claims in Mirna Patent Application on let-7

Premium

Mirna Therapeutics said this week that the US Patent and Trademark Office has issued a notice of allowance for claims in a company-controlled patent application related to the therapeutic use of the let-7 microRNA.

Mirna said that, along with collaborators at Yale University, it has shown that let-7 regulates "multiple cancer-related genes and pathways, influences the sensitivity of cancer cells to radiation and chemotherapy, and affects tumor development."

Additional work has demonstrated that altered expression of let-7 is important in cancer stem cell development and that the miRNA can inhibit metastasis.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.